University of Minnesota Medical School researchers have shown that reducing chronic inflammation can significantly protect ...
University of Minnesota Medical School researchers have shown that reducing chronic inflammation can significantly protect against age-related macular degeneration (AMD)-like pathology in preclinical ...
A wireless implant helped patients with severe macular degeneration regain usable vision. The results point toward a new ...
ANNX advances tanruprubart for Guillain-Barré syndrome, with an EMA filing planned for January 2026 and ongoing FDA ...
The nods allow Regeneron to better compete with Roche, which stormed the market in 2022 with Vabysmo. The Swiss drugmaker's ...
We’re excited to present a review of our robust data package at OIS, highlighting our momentum toward advancing this innovation into clinical evaluation.” About VLTR-559 VLTR-559 is a long-acting anti ...
Pharmaceutical Technology on MSN
Regeneron’s Eylea franchise boosted by pair of FDA approvals
Regeneron has won two US Food and Drug Administration (FDA) approvals for Eylea HD (aflibercept), adding another indication ...
First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing ...
On track to report topline 56-week data for LUGANO in mid-2026 with LUCIA data to closely follow – WATERTOWN, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a ...
The gene therapy will utilize the firm's suprachoroidal vector coAAV-SCS, which it says will be an effective and less burdensome treatment alternative.
Outlook Therapeutics Inc. (NASDAQ:OTLK) surged 17.2% in premarket trading Thursday after announcing that the U.S. Food and ...
Outlook Therapeutics (OTLK) stock rises as the company's wet AMD therapy ONS-5010 undergoes FDA review, with a decision ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback